P53 Her2/neu as prognostic factors in advanced non-small cell lung cancer (NSCLC) treated with paclitaxel

被引：0
|
作者：
Yumuk, R
Turhal, N
Ahiskali, R
Gumus, M
Hatabay, N
Turken, O
Ozkan, A
Salepci, T
Aliustaoglu, M
机构：
[1] Marmara Univ Hosp, Div Med Oncol, Istanbul, Turkey
[2] Marmara Univ Hosp, Dept Pathol, Istanbul, Turkey
[3] Dr Lutfi Kirdar Res & Training Hosp, Oncol Unit, Istanbul, Turkey
[4] SSK Sureyyapasa Chest & Cardiovasc Dis Hosp, Oncol Unit, Istanbul, Turkey
[5] Gulhane Mil Med Acad, Div Med Oncol, Istanbul, Turkey
[6] Haydarpasa Numune Res & Training Hosp, Oncol Unit, Istanbul, Turkey
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S152 / S152
页数：1
相关论文
共 50 条
  • [1] p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer
    Fijolek, J.
    Wiatr, E.
    Rowinska-Zakrzewska, E.
    Giedronowicz, D.
    Langfort, R.
    Chabowski, M.
    Orlowski, T.
    Roszkowski, K.
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2006, 21 (02): : 81 - 87
  • [2] Prognostic value of p53 abnormalities in non-small cell lung cancer (NSCLC)
    Niklinski, J
    Chyczewski, L
    Niklinska, W
    Laudanski, J
    Furman, M
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S248 - S248
  • [3] Prognostic significance of intracellular laminin and Her2/neu overexpression in non-small cell lung cancer
    Szelachowska, Jolanta
    Jelen, Michal
    Kornafel, Jan
    [J]. ANTICANCER RESEARCH, 2006, 26 (5B) : 3871 - 3876
  • [4] P53 as a prognostic indicator in non-small cell lung cancer
    Tsobanidou, Ch.
    Papageorgiou, A.
    Anestakis, D.
    Paraskevopoulos, P.
    Angel, J.
    Toliou, Th.
    [J]. LUNG CANCER, 2006, 52 : S39 - S39
  • [5] Smoking and prognostic factors in advanced non-small cell lung cancer (NSCLC)
    Altug, S.
    Li, C.
    Marek, M.
    Guclu, S.
    Kim, Y.
    Meshref, M.
    Qin, S.
    Krejcy, K.
    Reece, W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Lack of prognostic significance of immunohistochemical detection of p53 in non-small cell lung cancer (NSCLC)
    Pfeiffer, P
    Clausen, PP
    Andersen, K
    Rose, C
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1102 - 1102
  • [7] Weekly paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC).
    Nakagawa, K
    Fukuoka, M
    Saijo, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 704S - 704S
  • [8] The role of HER2/neu expression and trastuzumab in non-small cell lung cancer
    Hirsch, FR
    Langer, CJ
    [J]. SEMINARS IN ONCOLOGY, 2004, 31 (01) : 75 - 82
  • [9] EGFR and HER2/NEU in gefitinib chemotherapy for non-small cell lung cancer
    Yoo, J.
    [J]. HISTOPATHOLOGY, 2008, 53 : 406 - 406
  • [10] The Prognostic Significance of HER2 Overexpression in Non-small Cell Lung Cancer
    Takenaka, Masaru
    Hanagiri, Takeshi
    Shinohara, Shinji
    Kuwata, Taiji
    Chikaishi, Yasuhiro
    Oka, Soich
    Shigematsu, Yoshiki
    Nagata, Yoshika
    Shimokawa, Hidehiko
    Nakagawa, Makoto
    Uramoto, Hidetaka
    So, Tomoko
    Tanaka, Fumihiro
    [J]. ANTICANCER RESEARCH, 2011, 31 (12) : 4631 - 4636
12345